182 related articles for article (PubMed ID: 26676972)
1. Identification of miR-15b as a transformation-related factor in mantle cell lymphoma.
Arakawa F; Kimura Y; Yoshida N; Miyoshi H; Doi A; Yasuda K; Nakajima K; Kiyasu J; Niino D; Sugita Y; Tashiro K; Kuhara S; Seto M; Ohshima K
Int J Oncol; 2016 Feb; 48(2):485-92. PubMed ID: 26676972
[TBL] [Abstract][Full Text] [Related]
2. The Wnt signaling pathway and mitotic regulators in the initiation and evolution of mantle cell lymphoma: Gene expression analysis.
Kimura Y; Arakawa F; Kiyasu J; Miyoshi H; Yoshida M; Ichikawa A; Niino D; Sugita Y; Okamura T; Doi A; Yasuda K; Tashiro K; Kuhara S; Ohshima K
Int J Oncol; 2013 Aug; 43(2):457-68. PubMed ID: 23760751
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.
Iqbal J; Shen Y; Liu Y; Fu K; Jaffe ES; Liu C; Liu Z; Lachel CM; Deffenbacher K; Greiner TC; Vose JM; Bhagavathi S; Staudt LM; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; McKeithan TW; Chan WC
Blood; 2012 May; 119(21):4939-48. PubMed ID: 22490335
[TBL] [Abstract][Full Text] [Related]
4. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.
Gallo M; Cacheux V; Vincent L; Bret C; Tempier A; Guittard C; Macé A; Leventoux N; Costes V; Szablewski V
Virchows Arch; 2016 Dec; 469(6):697-706. PubMed ID: 27605053
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma.
Satzger I; Mattern A; Kuettler U; Weinspach D; Voelker B; Kapp A; Gutzmer R
Int J Cancer; 2010 Jun; 126(11):2553-62. PubMed ID: 19830692
[TBL] [Abstract][Full Text] [Related]
6. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.
Zhao JJ; Lin J; Lwin T; Yang H; Guo J; Kong W; Dessureault S; Moscinski LC; Rezania D; Dalton WS; Sotomayor E; Tao J; Cheng JQ
Blood; 2010 Apr; 115(13):2630-9. PubMed ID: 20086245
[TBL] [Abstract][Full Text] [Related]
7. Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation.
Menke JR; Vasmatzis G; Murphy S; Yang L; Menke DM; Tun HW; King RL; Smoley SA; Ketterling RP; Sukov WR
Hum Pathol; 2017 Jun; 64():207-212. PubMed ID: 28132860
[TBL] [Abstract][Full Text] [Related]
8. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Husby S; Ralfkiaer U; Garde C; Zandi R; Ek S; Kolstad A; Jerkeman M; Laurell A; Räty R; Pedersen LB; Pedersen A; Ehinger M; Sundström C; Karjalainen-Lindsberg ML; Delabie J; Clasen-Linde E; Brown P; Cowland JB; Workman CT; Geisler CH; Grønbæk K
Blood; 2015 Apr; 125(17):2669-77. PubMed ID: 25736311
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
10. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
Isaac KM; Portell CA; Williams ME
Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
[TBL] [Abstract][Full Text] [Related]
11. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
[TBL] [Abstract][Full Text] [Related]
12. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma: transcriptional regulation by microRNAs.
Di Lisio L; Gómez-López G; Sánchez-Beato M; Gómez-Abad C; Rodríguez ME; Villuendas R; Ferreira BI; Carro A; Rico D; Mollejo M; Martínez MA; Menárguez J; Díaz-Alderete A; Gil J; Cigudosa JC; Pisano DG; Piris MA; Martínez N
Leukemia; 2010 Jul; 24(7):1335-42. PubMed ID: 20485376
[TBL] [Abstract][Full Text] [Related]
15. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
[TBL] [Abstract][Full Text] [Related]
17. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
19. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
20. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.
Clot G; Jares P; Giné E; Navarro A; Royo C; Pinyol M; Martín-Garcia D; Demajo S; Espinet B; Salar A; Ferrer A; Muntañola A; Aymerich M; Rauert-Wunderlich H; Jaffe ES; Connors JM; Gascoyne RD; Delabie J; López-Guillermo A; Ott G; Wright GW; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; Beà S; Campo E
Blood; 2018 Jul; 132(4):413-422. PubMed ID: 29769262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
